New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
10:30 EDTCELGNICE says better information needed on Celgene's Revlimid
The National Institute for Health and Care Excellence, the U.K.'s healthcare guidance body, issued new draft guidance on the use of Revlimid's lenalidomide, trade name Celgene, for treating the blood cancer multiple myeloma after one prior treatment with bortezomib. NICE said, "With the current information available, the committee's preliminary guidance, now being issued for consultation, does not recommend lenalidomide for this indication." NICE's Chief Executive, Sir Andrew Dillon, said: “In the original guidance published in 2009, NICE recommended lenalidomide as treatment option for multiple myeloma in people who have received two or more prior therapies. This recommendation has not changed and patients at that stage in the treatment pathway will still be able to receive lenalidomide through the NHS." Reference Link
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
20:10 EDTCELGCelgene says patent challenges are baseless, Reuters reports
Subscribe for More Information
July 28, 2015
07:31 EDTCELGCelgene commences tender offer for Receptos
Subscribe for More Information
July 27, 2015
10:40 EDTCELGIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
08:38 EDTCELGAnalysts divided on Biogen following $85 selloff
Subscribe for More Information
July 24, 2015
08:08 EDTCELGCelgene price target raised to $190 from $156 at Canaccord
Subscribe for More Information
July 23, 2015
19:50 EDTCELGCelgene price target raised to $163 from $146 at Cantor
Subscribe for More Information
10:50 EDTCELGCelgene positioned for sustainable growth, says Piper Jaffray
Subscribe for More Information
07:37 EDTCELGCelgene reports Q2 Revlimid sales up 19% to $1.44B
ABRAXANE® sales for the second quarter were $244 million, a 13 percent increase. POMALYST®/IMNOVID® sales for the second quarter were $235 million, an increase of 46%. VIDAZA® sales in the second quarter remained flat year-over-year at $152 million. OTEZLA® sales for the second quarter were $90 million, increasing 49 percent over the first quarter of 2015.
07:37 EDTCELGCelgene raises FY15 adjusted EPS view to $4.75-$4.85 from $4.60-$4.75
Subscribe for More Information
07:32 EDTCELGCelgene reports Q2 adjusted EPS $1.23, consensus $1.20
Subscribe for More Information
July 22, 2015
15:26 EDTCELGNotable companies reporting before tomorrow's open
Subscribe for More Information
09:28 EDTCELGBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
July 21, 2015
11:03 EDTCELGCelgene treatment of pediatric Crohn's disease receives FDA orphan designation
Subscribe for More Information
06:29 EDTCELGCelgene price target raised to $160 from $147 at Piper Jaffray
Subscribe for More Information
06:24 EDTCELGPiper expects 'stronger, bolder' move from Biogen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use